Medicinova (MNOV) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Medicinova (MNOV) has outperformed PDS Biotechnology (PDSB) over the past year, gaining 26.2% versus a gain of 2.0%. Over five years, MNOV leads with a -59.7% price change compared with -91.7% for PDSB. Medicinova is the larger company by market cap ($75.8 million vs $73.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNOV | PDSB |
|---|---|---|
| Share price | $1.54 | $1.02 |
| Market cap | $75.80M | $73.92M |
| 1-day change | -4.35% | -4.23% |
| YTD return | +17.56% | +32.47% |
| 1-year return | +26.23% | +2.00% |
| 5-year return | -59.69% | -91.73% |
| EPS (TTM) | $-0.21 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.90 | $1.55 |
| 52-week low | $1.17 | $0.195 |
| Distance from 52-week high | -60.51% | -34.19% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +435.71% | +390.20% |
| Average volume | 322.57K | 23.24M |
| Shares outstanding | 49.22M | 72.47M |
| Employees | 6 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNOV has outperformed PDSB by 24.2 percentage points over the past year.
About Medicinova
MNOV stock →MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
MNOV vs PDSB FAQ
Which is bigger, Medicinova or PDS Biotechnology?
Medicinova (MNOV) is larger, with a market capitalization of $75.80M compared with $73.92M for PDS Biotechnology (PDSB).
Which stock has performed better over the past year, MNOV or PDSB?
MNOV returned +26.23% over the past 12 months, compared with +2.00% for PDSB (price return, excluding dividends). Past performance does not predict future results.
Are Medicinova and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.